
Top insights from the Endpoints at ASCO McKesson leadership panel
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportReforming healthcare data analytics with advanced technologies and automation, ensuring high-fidelity, analytics-ready data for life sciences.
Read Time: 3.5 minutes
It’s no secret that biopharma companies deploy ever-increasing volumes of data to fuel the development and distribution of lifesaving medications and therapies. And, as innovators embrace new technologies, data demands will continue growing.
But all data is not created equal, and data quality can mean the difference between success or failure of any initiative.
Meet Compile – now McKesson Compile™ – a provider of healthcare intelligence and high-capture, high-fidelity patient and provider aggregated data. McKesson Compile’s provider data maps the complex and always-changing relationships between healthcare providers (HCPs) and their affiliations with healthcare organizations (HCOs), enabling life sciences companies to get a full picture of their target market.
McKesson Compile’s patient data includes multiple sources of medical and pharmaceutical claims data (commercial, Medicare, Medicaid), social determinants of health (SDoH) and electronic health record (EHR) data across all therapeutic areas.
McKesson recently acquired Compile to meet current and future demand for data used to assist in the development of new therapies. Additionally, the combined business will now have the opportunity to offer products informed by McKesson's extensive data footprint, which has been built over decades through collaborations with biopharma companies, care providers, pharmacies, and others.
Here are five compelling insights you should know about McKesson Compile.
#1) They do the work to make data analytics ready and usable.
McKesson Compile’s ReadyData™ is crafted to use right out of the box. It enables life sciences companies to do their analyses faster, freeing highly skilled analysts from cleaning and organizing data before work begins.
To help ensure the usability of ReadyData, McKesson Compile does the cleansing, normalizing, deduping, and table-merging clean up. It then enhances the data with modeled variables and assigns missing values, creating a more complete dataset and helping to streamline analyses.
In short, McKesson Compile does the dirty work.
McKesson Compile’s proprietary ingestion and normalization process preps data for high-fidelity analytics
#2) They use sophisticated technology for better data quality.
In the real world, there are many connections between healthcare professionals (HCPs) and healthcare organizations (HCOs). These connections can include being co-workers or co-authors, and HCPs can have different roles within HCOs, such as being an employed physician or a referring physician. Storing and representing these connections in a dataset is difficult. To address this challenge, McKesson Compile uses a graph processing engine, which is a sophisticated way of organizing data that keeps track of these complex relationships in a 3D-like format. This graph processing engine allows for more detailed information in the Provider 360 ReadyData product compared to a traditional table-based approach, which can lead to loss of information.
Illustration of how an in-memory graph processing engine captures HCP-HCO relationships
#3) Automation is a key part of the McKesson Compile difference.
McKesson Compile’s tech-forward automated approach to data gathering captures and triangulates thousands of diverse sources for higher data accuracy. Unlike some data providers, McKesson Compile doesn’t rely on phone calls or surveys, which can quickly lead to outdated information, but instead scours and ingests information on an ongoing and regular basis.
McKesson Compile ingests data from myriad purchased and public data sources such as medical claims data, SEC filings, IRS filings, provider websites, social media, payer directories, life science journals, Medicaid Directories, licensing information and more.
4) McKesson Compile prioritizes quick and knowledgeable customer service.
McKesson Compile is structured to deliver premium customer service and exceed the industry standard—primarily because they employ life sciences and data experts who are genuinely helpful and collaborative. McKesson Compile’s customer service team also prioritizes speed – with the goal of responding to questions within one business day or less. The McKesson Compile team listens carefully to customers’ business goals, helps them define their data needs, and responds to questions as they use the data.
And data procurement is ultra-fast as well, with access to data available typically only 48 hours after contract signing.
#5) McKesson Compile is ready for the future of the data industry.
The healthcare industry’s demand for data continues to accelerate—especially as companies deploy AI and Machine Learning (ML)-enabled applications. McKesson Compile has recently built an advanced processor to ingest new data sources in weeks. The speed at which new data is ingested into the system enables them to add various data sources to continuously enhance new products quickly.
Along with novel data sources, AI and ML require high volumes of clean data. McKesson Compile’s ReadyData process ensures that data sets are as clean and complete as possible, thus enabling AI to reach its greatest potential.
Top insights from the Endpoints at ASCO McKesson leadership panel
Insights and Takeaways for The Next Chapter in Specialty Medicine from Asembia AXS25
Enhancing patient access and engagement in clinical trials.
Learn how InspiroGene is helping deliver revolutionary cell and gene therapies to patients in need.
Insights from the 2025 CoverMyMeds Medication Access Report, From Barriers to Bridges
For two years in a row, McKesson has partnered with customers and industry partners to bring health education and awareness of resources to members of the Navajo community.
Learn more about RxOwnership, McKesson’s strategic consultants who help independent pharmacy owners navigate challenges, optimize operations and achieve financial health.
During the recent STAT @ ASH event in San Diego, panelists explored the role of community oncology in advancing precision medicine for cancer care.
Learn about McKesson’s new Cell and Gene Therapy (CGT) brand, InspiroGene, and the launch of a first-of-its-kind report about the CGT landscape and its future trajectory.
Milken Institute Future of Health Summit panelists address critical industry challenges and explore ways to futureproof the pharmaceutical supply chain.